XBiotech (XBIT) Free Cash Flow (2014 - 2025)
XBiotech (XBIT) posted quarterly Free Cash Flow of -$22.7 million for Q4 2025, down 243.69% year-over-year from $15.8 million in Q4 2024, and down 419.5% quarter-over-quarter from -$4.4 million in Q3 2025.
XBiotech (XBIT) Free Cash Flow (2014 - 2025) Analysis & Trends
XBiotech's Free Cash Flow history runs 12 years deep, the most recent figure standing at -$22.7 million for Q4 2025.
- In Q4 2025, Free Cash Flow fell 243.69% year-over-year to -$22.7 million; the TTM figure through Dec 2025 stood at -$39.9 million (down 28.64% YoY), while the FY2025 annual figure was -$39.9 million, down 28.64% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$22.7 million, down from -$4.4 million in the prior quarter.
- The five-year high for Free Cash Flow was $70.6 million in Q2 2021, with the low at -$22.7 million in Q4 2025.
- The 5-year median for Free Cash Flow is -$4.9 million (2023), against an average of -$1.8 million.
- The sharpest annual moves came in 2021 and 2022: Free Cash Flow jumped 712.03% in 2021, then sank 413.85% in 2022.
- XBiotech's Free Cash Flow stood at $1.2 million in 2021, then slumped by 327.99% to -$2.7 million in 2022, then decreased by 17.44% to -$3.2 million in 2023, then plunged by 106.05% to -$6.6 million in 2024, then sank by 243.69% to -$22.7 million in 2025.
- Business Quant data shows XBIT's Free Cash Flow at -$22.7 million in Q4 2025, -$4.4 million in Q3 2025, and -$6.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 292.04 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -95.09 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 477.44 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 433.84 Mn |
| 10 | XBiotech | 68.90 Mn | 68.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -22.70 Mn |
| Dec 31, 2025 | -22.70 Mn |
| Sep 30, 2025 | -4.37 Mn |
| Sep 30, 2025 | -4.37 Mn |
| Jun 30, 2025 | -6.04 Mn |
| Jun 30, 2025 | -6.04 Mn |
| Mar 31, 2025 | -6.81 Mn |
| Mar 31, 2025 | -6.81 Mn |
| Dec 31, 2024 | -6.60 Mn |
| Dec 31, 2024 | -6.60 Mn |
| Sep 30, 2024 | -4.97 Mn |
| Sep 30, 2024 | -4.97 Mn |
| Jun 30, 2024 | -12.18 Mn |
| Jun 30, 2024 | -12.18 Mn |
| Mar 31, 2024 | -7.28 Mn |
| Mar 31, 2024 | -7.28 Mn |
| Dec 31, 2023 | -3.21 Mn |
| Dec 31, 2023 | -3.21 Mn |
| Sep 30, 2023 | -1.52 Mn |
| Sep 30, 2023 | -1.52 Mn |